Enhanced Review Capacity Initiative
On this page:
About the Enhanced Review Capacity Initiative
The number and complexity of new pharmaceuticals and medical devices seeking approval for sale in Canada, as well as their associated scientific issues, is increasing every day. To meet this demand, Health Canada's Therapeutic Products Directorate (TPD) is introducing business improvements to its review process.
The Enhanced Review Capacity Initiative, a component of Health Canada's Therapeutic Access Strategy (TAS) and TPD's Business Transformation Strategy, is designed to increase TPD's capacity to deliver quality, timely decisions on pharmaceuticals and medical devices for human use. The initiative will build TPD's internal scientific capacity, increase corporate flexibility to meet performance targets, support long-term human resources planning and training, and provide an enhanced ability to draw on external scientific expertise.
As part of this initiative, TPD's Office of Business Transformation has established the Enhanced Review Capacity Unit. A key function of this unit is to provide centralized contracting services to facilitate the appropriate use of expert advice from external sources, such as drug or disease experts, professional associations, scientific advisory committees or panels and academic institutions.
In order to be able to access experts quickly and efficiently, The Scientific Experts Inventory Database has been developed. It lists medical and scientific professionals, such as drug, disease and medical device experts, health researchers, and clinicians who have been pre-screened and pre-qualified, thereby enabling faster and more accurate identification of individuals available to support and supplement the internal TPD review team as required.
For information on how you can become part of TPD's Scientific Experts Database and Inventory please see our Letter of Invitation.
Report a problem or mistake on this page
- Date modified: